watch
Cell Therapeutics, Inc.

Cell Therapeutics, Inc.

Sector: Medical Laboratories Region: WA, United States


: | Nasdaq: CTIC | Milan Stock Exchange: CTIC | Berlin Stock Exchange: CEPR


Similar to: EpiStem Holdings Plc

Cell Therapeutics, Inc. operates as a biopharmaceutical company, which is focused on the acquisition, development, and commercialization of less toxic and more effective ways to treat cancer. Its products include Pixuvri, OPAXIO, Brostallicin and Bisplatinates. Pixuvri is a novel anthracycline derivative used for the treatment of hematologic malignancies and solid tumors. Pixuvri was studied in its EXTEND or PIX301, clinical trial, which is the first randomized, controlled, phase III single-agent clinical trial of Pixuvri for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma or NHL, who received two or more prior therapies and who were sensitive to treatment with anthracyclines. OPAXIO is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. Brostallicin is a new class of cancer drug-a synthetic DNA minor groove binding agent with a unique mechanism of action. Brostallicin is currently in a phase II trial for the treatment of metastatic triple-negative breast cancer. Bisplatinates is a platinum-based chemotherapy drug used to treat a wide variety of cancers. The company's technologies include Polyglutamate Drug Delivery, Genetic Polymer and Context of vulnerability. The Polyglutamate Drug Delivery technology open the way to the selective delivery of cancer therapies to tumor tissue, potentially reducing the toxic side effects of widely used and well-characterized therapies. The Genetic Polymer technology supports the need for new rDNA-derived protein-based drugs by potentially extending plasma half-life. Cell Therapeutics was founded by James A. Bianco, Jack W. Singer and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

News & Analysis

You may also be interested in: